Adverse events430

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 430

Type	Event	Organ system	Group	Affected	At risk
other	Agitation	Psychiatric disorders	Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2	1	6
other	Agitation	Psychiatric disorders	Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2	1	3
other	Agitation	Psychiatric disorders	Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2	0	7
other	Agitation	Psychiatric disorders	Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2	0	9
other	Agitation	Psychiatric disorders	Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2	0	1
other	Anxiety	Psychiatric disorders	Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2	0	6
other	Anxiety	Psychiatric disorders	Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2	0	3
other	Anxiety	Psychiatric disorders	Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2	0	7
other	Anxiety	Psychiatric disorders	Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2	1	9
other	Anxiety	Psychiatric disorders	Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2	0	1
other	Decreased appetite	Metabolism and nutrition disorders	Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2	1	6
other	Decreased appetite	Metabolism and nutrition disorders	Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2	1	3
other	Decreased appetite	Metabolism and nutrition disorders	Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2	1	7
other	Decreased appetite	Metabolism and nutrition disorders	Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2	1	9
other	Decreased appetite	Metabolism and nutrition disorders	Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2	0	1
other	Dysgeusia	Nervous system disorders	Dasatinib, 100 mg QD/100 mg BID + Lomustine, 110 mg/m^2	0	6
other	Dysgeusia	Nervous system disorders	Dasatinib, 100 mg QD/100 mg BID + Lomustine, 90 mg/m^2	1	3
other	Dysgeusia	Nervous system disorders	Dasatinib, 100 mg BID + Lomustine, 90 mg/m^2	0	7
other	Dysgeusia	Nervous system disorders	Dasatinib, 150 mg/d + Lomustine, 90 mg/m^2	1	9
other	Dysgeusia	Nervous system disorders	Dasatinib, 100 mg/d QD + Lomustine, 90 mg/m^2	0	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00948389/events

API reference For AI assistants

Adverse events430

Sources 3

Read this list from software.